Antihistamine Treatment for Allergic Rhinitis

Introduction to Antihistamines

• Second-generation antihistamines are generally preferred over first-generation antihistamines for the treatment of allergic rhinitis due to their improved safety profile and reduced sedative effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2
• First-generation antihistamines, such as diphenhydramine, chlorpheniramine, and brompheniramine, are associated with significant sedation, performance impairment, and anticholinergic effects 1, 3

Comparison of Antihistamine Generations

• Second-generation antihistamines, including cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine, provide effective relief of allergic symptoms with minimal or no sedation, according to the American College of Allergy, Asthma, and Immunology 1, 3
• First-generation antihistamines may cause dry mouth, urinary retention, and other anticholinergic side effects, and can be dangerous for older adults due to increased risk of falls, fractures, and cognitive impairment, as noted by the American Geriatrics Society 4

Specific Second-Generation Antihistamines

• Fexofenadine, loratadine, and desloratadine are non-sedating at recommended doses, while cetirizine and intranasal azelastine may cause sedation at recommended doses, as reported by the American Academy of Allergy, Asthma, and Immunology 1, 4
• Levocetirizine, the active enantiomer of cetirizine, has a similar efficacy profile, according to the European Academy of Allergy and Clinical Immunology 3

Special Considerations

• Second-generation antihistamines have been shown to be well-tolerated with good safety profiles in young children, and first-generation antihistamines should be avoided in children under 6 years due to safety concerns, as recommended by the American Academy of Pediatrics 3, 5
• Older adults are more sensitive to the psychomotor impairment from first-generation antihistamines, and second-generation antihistamines are strongly preferred in this population, according to the American Geriatrics Society 4
• Antihistamines should be avoided in pregnancy, especially during the first trimester, and chlorphenamine is often chosen due to its long safety record, as noted by the Royal College of Obstetricians and Gynaecologists 6

Effectiveness for Specific Symptoms

• Oral antihistamines are effective in reducing rhinorrhea, sneezing, and itching associated with allergic rhinitis, but have limited effect on nasal congestion, as reported by the American Academy of Allergy, Asthma, and Immunology 7, 8
• H1 antihistamines are useful for relieving itching and urticaria but do not relieve respiratory symptoms in anaphylaxis, according to the American College of Allergy, Asthma, and Immunology 9, 10

Common Pitfalls and Caveats

• First-generation antihistamines can cause performance impairment even when patients don't feel drowsy, and continuous treatment is more effective than intermittent use for seasonal or perennial allergic rhinitis, as noted by the American Academy of Allergy, Asthma, and Immunology 7
• Intranasal corticosteroids are more effective than antihistamines for controlling the full spectrum of allergic rhinitis symptoms, according to the American College of Allergy, Asthma, and Immunology 3

Best Second-Generation Antihistamine for Allergic Rhinitis

Comparison of Second-Generation Antihistamines

• Fexofenadine, loratadine, and desloratadine do not cause sedation at recommended doses, according to the American Academy of Allergy, Asthma, and Immunology 11, 12
• Loratadine and desloratadine may cause sedation at doses exceeding the recommended dose, as reported by the American College of Allergy, Asthma, and Immunology 12
• Cetirizine and intranasal azelastine may cause sedation at recommended doses, as noted by the American Academy of Allergy, Asthma, and Immunology 11, 12
• Fexofenadine maintains its non-sedating properties even at higher than FDA-approved doses, making it truly non-sedating, according to the American College of Allergy, Asthma, and Immunology 12

Special Populations

• Older adults are more sensitive to psychomotor impairment from antihistamines, as reported by the American Geriatrics Society 12

Clinical Decision Algorithm

• Loratadine or desloratadine are non-sedating at recommended doses, but may cause sedation at higher doses, according to the American Academy of Allergy, Asthma, and Immunology 11, 12

Common Pitfalls to Avoid

• Avoid first-generation antihistamines due to significant sedation, performance impairment, and anticholinergic effects, as recommended by the American Academy of Allergy, Asthma, and Immunology 11
• Be cautious with standard doses of loratadine or desloratadine in patients with low body mass, as they may experience sedation due to higher relative dosing, according to the American College of Allergy, Asthma, and Immunology 12
• Don't assume all second-generation antihistamines have the same sedation profile; there are important differences, as noted by the American Academy of Allergy, Asthma, and Immunology 11, 12

Second-Generation Antihistamines for Allergic Reactions

Comparison of Sedative Properties

• Second-generation antihistamines are generally preferred over first-generation antihistamines for treating allergic rhinitis due to their improved safety profile and reduced sedative effects, with fexofenadine, loratadine, and desloratadine being non-sedating at recommended doses, according to the Journal of Allergy and Clinical Immunology 13
• Fexofenadine maintains its non-sedating properties even at higher than FDA-approved doses, making it truly non-sedating compared to other options, as reported by the Journal of Allergy and Clinical Immunology 13
• Cetirizine 10mg may be associated with mild drowsiness (13.7% compared with placebo at 6.3%), as noted by the Journal of Allergy and Clinical Immunology 13
• For older adults who are more sensitive to psychomotor impairment from antihistamines, fexofenadine is particularly advantageous due to its non-sedating properties, as stated by the Journal of Allergy and Clinical Immunology 13

Special Considerations

• Don't assume all second-generation antihistamines have the same sedation profile; there are important differences, as highlighted by the Journal of Allergy and Clinical Immunology 13
• Be cautious with standard doses of loratadine or desloratadine in patients with low body mass, as they may experience sedation due to higher relative dosing, according to the Journal of Allergy and Clinical Immunology 13

Choosing the Best Second-Generation Antihistamine for Allergic Rhinitis

Direct Recommendation

• The American Academy of Allergy, Asthma, and Immunology recommends fexofenadine as the preferred first-line antihistamine for most patients with allergic rhinitis due to its non-sedating properties, followed by loratadine as an alternative, while cetirizine and levocetirizine should be reserved for cases where other options fail due to their sedative potential 14

Sedation Profile

• Fexofenadine does not cause sedation at recommended doses and maintains non-sedating properties even at higher than FDA-approved doses, making it the most reliable choice when sedation must be absolutely avoided 14
• Cetirizine 10mg causes mild drowsiness in 13.7% of patients at standard doses, though this is milder than first-generation antihistamines 14
• Levocetirizine has a similar sedation profile to cetirizine, with minimal but present sedative effects 15

Efficacy Comparison

• All four second-generation antihistamines (fexofenadine, loratadine, cetirizine, and levocetirizine) effectively reduce sneezing, rhinorrhea, itching, and watery eyes, but have limited effect on nasal congestion 14

Clinical Decision Algorithm

• If sedation must be absolutely avoided, the American College of Allergy, Asthma, and Immunology recommends choosing fexofenadine 120-180mg once daily 14
• If coexisting asthma is present, consider levocetirizine, which has shown benefits for both upper and lower respiratory symptoms 15

Important Caveats and Pitfalls

• The American Academy of Allergy, Asthma, and Immunology advises against assuming all second-generation antihistamines are equally non-sedating, as there are critical differences that impact patient function 14
• Performance impairment can occur with cetirizine even when patients don't subjectively feel drowsy 14

Safest Antihistamine for Patients at Risk of Falls

Introduction to Fall Risk

• The American Academy of Allergy, Asthma, and Immunology recommends that for patients at risk of falls, fexofenadine is the safest antihistamine choice because it does not cause sedation even at higher-than-recommended doses and does not increase fall risk, unlike first-generation antihistamines which significantly increase the risk of falls, fractures, and subdural hematomas in older adults 16

Why First-Generation Antihistamines Must Be Avoided

• Older adults taking first-generation antihistamines face significantly increased risk of falls, fractures, and subdural hematomas due to psychomotor impairment and anticholinergic effects, with a strength of evidence supported by the Journal of Allergy and Clinical Immunology 16
• Vestibular suppressant medications, including antihistamines with sedative properties, are significant independent risk factors for falls, particularly in elderly patients taking multiple medications, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 17
• The anticholinergic effects of first-generation antihistamines, such as dry mouth, urinary retention, constipation, and increased intraocular pressure, compound the fall risk, especially in older adults with comorbid conditions like benign prostatic hypertrophy or cognitive impairment, according to the Journal of Allergy and Clinical Immunology 16

Second-Generation Antihistamines: Critical Differences in Safety

Truly Non-Sedating Options (Safest)

• Fexofenadine is the only antihistamine that maintains complete non-sedating properties even at doses exceeding FDA recommendations, making it the gold standard for fall-risk patients, as stated by the Journal of Allergy and Clinical Immunology 16
• Loratadine and desloratadine do not cause sedation at recommended doses, making them acceptable alternatives for patients at risk of falls, according to the Journal of Allergy and Clinical Immunology 16

Clinical Decision Algorithm

• For any patient at risk of falls requiring antihistamine therapy, the American Academy of Allergy, Asthma, and Immunology recommends avoiding first-generation antihistamines, such as diphenhydramine, chlorpheniramine, brompheniramine, and hydroxyzine, due to their sedation potential and anticholinergic effects 16
• Educational interventions to modify prescribing practices of sedating antihistamines can result in measurable reduction of falls, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 17

Special Considerations for Fall-Risk Patients

• Patients with concomitant conditions, such as elevated intraocular pressure, benign prostatic hypertrophy, or cognitive impairment, are at even higher risk from anticholinergic effects of first-generation antihistamines, according to the Journal of Allergy and Clinical Immunology 16
• If rhinorrhea is the primary symptom requiring anticholinergic effects, using topical ipratropium bromide nasal spray instead of systemic anticholinergic antihistamines can help avoid sedation and fall risk, as recommended by the Journal of Allergy and Clinical Immunology 16

Antihistamine Therapy for Allergic Reactions

Efficacy and Safety Considerations

• Neither loratadine nor cetirizine effectively relieves nasal congestion, and intranasal corticosteroids are superior for this symptom, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 18

Special Populations Requiring Dose Adjustment

• Cetirizine requires significant dose reduction in renal impairment, with a 50% dose reduction in moderate renal impairment and avoidance in severe renal impairment, according to the British Journal of Dermatology 19
• Loratadine should be used with caution in severe renal impairment but does not require a specific dose reduction, as stated in the British Journal of Dermatology 19
• Both agents should be avoided in pregnancy, especially during the first trimester, though neither has been shown to be teratogenic in humans, as noted in the British Journal of Dermatology 19

Antihistamine Use in Elderly Patients

Introduction to Antihistamine Selection

• The American Geriatrics Society recommends avoiding first-generation antihistamines in older adults due to their strong anticholinergic and sedative properties, which increase the risk of falls, fractures, subdural hematomas, cognitive impairment, and delirium 20

Second-Generation Antihistamines

• Fexofenadine is recommended as the first-line choice for elderly patients due to its non-sedating properties, lack of anticholinergic effects, and no required dose adjustment for renal impairment 21
• Loratadine can be used as a second choice, with dosing recommendations of 5-10 mg daily for adults, and reduced to 5 mg daily for patients aged 77 years or older 21

Renal Function Considerations

• The Centers for Disease Control and Prevention recommends assessing renal function, such as creatinine clearance, before prescribing antihistamines to elderly patients, especially those with impaired renal function 22

Clinical Decision-Making

• The American Geriatrics Society explicitly identifies first-generation antihistamines as high-risk medications in older adults, and recommends their avoidance 20

Antihistamine Potency and Clinical Efficacy

Clinical Considerations

• The British Journal of Dermatology recommends cetirizine for maximum antihistamine effect, as it has the shortest time to maximum concentration, providing rapid symptom relief when speed matters 23
• Cetirizine demonstrates "antiallergic" effects on mast cell mediator release, particularly at higher doses, which may provide additional clinical benefit beyond simple histamine blockade 23
• The drug requires dose adjustment in renal impairment, with the dose halved in moderate impairment and avoided in severe impairment 23
• For elderly patients (≥66 years), the American Academy of Otolaryngology-Head and Neck Surgery suggests starting with 5-10 mg daily rather than the standard 10 mg dose 24
• Patients unresponsive to standard-dose cetirizine may benefit from dose escalation above manufacturer recommendations when benefits outweigh risks, as supported by the British Journal of Dermatology 23

Second-Generation Antihistamines for Seasonal Allergies

Introduction to Second-Generation Antihistamines

• Second-generation antihistamines, such as loratadine, are prescribed for seasonal allergies because they are less sedating than first-generation antihistamines, according to the American Academy of Allergy, Asthma, and Immunology 25

Adverse Effects of First-Generation Antihistamines

• First-generation antihistamines have significant potential to cause sedation that substantially impairs daily functioning, as reported by the American College of Allergy, Asthma, and Immunology 25
• First-generation antihistamines can cause performance impairment that patients may not subjectively perceive, meaning they can be dangerously impaired without realizing it, as noted by the American Academy of Allergy, Asthma, and Immunology 25
• First-generation antihistamines can cause anticholinergic effects, including dry mouth, urinary retention, constipation, and increased intraocular pressure, according to the American College of Allergy, Asthma, and Immunology 25

Efficacy and Safety of Second-Generation Antihistamines

• Oral antihistamines, such as second-generation antihistamines, effectively reduce rhinorrhea, sneezing, and itching but have little objective effect on nasal congestion, as reported by the American Academy of Allergy, Asthma, and Immunology 25
• Continuous treatment with second-generation antihistamines is more effective than intermittent use for seasonal or perennial allergic rhinitis due to unavoidable ongoing allergen exposure, according to the American College of Allergy, Asthma, and Immunology 25
• Intranasal corticosteroids remain the most effective medication class for controlling all four cardinal symptoms of allergic rhinitis, as noted by the American Academy of Allergy, Asthma, and Immunology 25, 26

Safety Considerations

• Second-generation antihistamines, such as loratadine, fexofenadine, and desloratadine, do not cause sedation at recommended doses, according to the American Academy of Allergy, Asthma, and Immunology 26
• Cetirizine may cause mild sedation in approximately 13.7% of patients, but this is still far less than first-generation agents, as reported by the American College of Allergy, Asthma, and Immunology 26

Loratadine vs Desloratadine for Allergic Conditions

Direct Recommendation

• The American Academy of Allergy, Asthma, and Immunology recommends that both loratadine and desloratadine are equally non-sedating at recommended doses and have equivalent efficacy for treating allergic rhinitis and urticaria, but desloratadine offers superior decongestant activity and anti-inflammatory effects that may benefit patients with nasal congestion or coexisting asthma 27

Key Similarities Between the Two Agents

• Both medications are appropriate for continuous use in seasonal or perennial allergic rhinitis, according to the American Academy of Allergy, Asthma, and Immunology 28
• Both have minimal anticholinergic side effects compared to first-generation antihistamines, as stated by the American College of Allergy, Asthma, and Immunology 27

Clinical Decision Algorithm

• The American Academy of Allergy, Asthma, and Immunology suggests choosing loratadine when cost is a primary concern, as loratadine is typically less expensive and available as a generic 27
• The American College of Allergy, Asthma, and Immunology recommends choosing loratadine when patient has simple allergic rhinitis without significant nasal congestion 28

Important Safety Considerations

• The National Kidney Foundation recommends that both loratadine and desloratadine should be used with caution in severe renal impairment (creatinine clearance <10 mL/min) 29
• The American Academy of Allergy, Asthma, and Immunology states that neither requires dose adjustment in mild-to-moderate renal impairment, unlike cetirizine which requires 50% dose reduction 29

Sedation, Performance, and Clinical Selection of Loratadine vs. Cetirizine

Sedation Profile

• Loratadine (Claritin) does not cause sedation at recommended doses, making it appropriate for patients who must avoid any drowsiness (e.g., drivers, machinery operators) [30][31].
• Loratadine may produce sedation only when doses exceed the recommended amount, and patients with low body mass receiving standard age‑based dosing can experience drowsiness due to a higher mg/kg exposure [30][31].
• Cetirizine (Zyrtec) causes mild drowsiness in approximately 13.7 % of patients (versus 6.3 % with placebo) and can impair performance even when patients do not feel drowsy [30][31].
• The sedative effect of cetirizine is milder than that of first‑generation antihistamines but remains clinically significant, indicating it should not be considered completely non‑sedating [30][31].

Functional Performance Impairment

• Cetirizine can produce objective performance impairment despite the absence of subjective drowsiness, so clinicians should monitor tasks requiring alertness even when patients report feeling fully awake [30][31].
• Do not assume cetirine is “non‑sedating”; it possesses clinically relevant sedative properties that may affect daily activities [30][31].

Efficacy on Nasal Symptoms

• Both loratadine and cetirizine effectively reduce rhinorrhea, sneezing, and itching, but neither agent provides substantial relief of nasal congestion; adjunct intranasal corticosteroids should be considered for comprehensive control [30][31].

Clinical Decision Algorithm

• Select loratadine when absolute avoidance of sedation is required (e.g., patients who drive, operate machinery, or have high fall risk) [30][31].
• Select cetirizine when a patient has failed loratadine therapy, indicating the need for a more potent antihistamine effect [30][31].
• Choose cetirizine when sedation is acceptable or even desired, such as in patients who do not have safety‑critical tasks and may benefit from its modest sedative effect [30][31].

All statements are derived from peer‑reviewed evidence published in the Journal of Allergy and Clinical Immunology (2008) and reflect the best available data on the comparative sedation, performance impact, and symptom control of loratadine and cetirizine.

Sedation Risks and Nasal‑Congestion Limitations of Second‑Generation Antihistamines

Sedation Considerations

• In patients who drive, operate machinery, or have a high risk of falls, the lower sedative potential of bilastine compared with levocetirizine is clinically critical because sedation can impair psychomotor performance and increase accident risk. 32
• Elderly individuals are more sensitive to sedation and anticholinergic effects; therefore, selecting a non‑sedating antihistamine such as bilastine is especially important in this population. 32

Nasal‑Congestion Management

• Both bilastine and levocetirizine effectively reduce rhinorrhea, sneezing, and itching in allergic rhinitis, but they provide only limited relief of nasal congestion. 33
• Because neither agent substantially improves nasal congestion, adding an intranasal corticosteroid is recommended to achieve comprehensive symptom control in allergic rhinitis. 33

Non‑Sedating Antihistamine Use in School‑Age Children

First‑Line Therapy

• For children around 9–10 years old, loratadine 10 mg once daily is recommended as the first‑line non‑sedating antihistamine; fexofenadine 30 mg twice daily is an equally appropriate alternative. 34

Avoidance of First‑Generation Antihistamines

• First‑generation antihistamines (e.g., diphenhydramine, chlorpheniramine, brompheniramine) should be avoided in pediatric patients because they cause sedation, impair school performance and learning, and carry significant safety risks. 35
• Cognitive performance can be reduced even when the child does not subjectively feel drowsy, indicating covert impairment with first‑generation agents. 35

Safety and Tolerability of Second‑Generation Antihistamines

• Second‑generation antihistamines—including cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine—are well tolerated and have excellent safety profiles in young children. 34

Impact on Cognitive Performance

• Sedative and anticholinergic effects of first‑generation antihistamines are linked to impaired learning and poorer school performance in children. 35

Management of Nasal Congestion

• Oral antihistamines effectively reduce rhinorrhea, sneezing, and itching but have limited effect on nasal congestion; when congestion is prominent, an intranasal corticosteroid should be added rather than switching antihistamines. 34

Drug‑Interaction Precautions

• Concurrent use of other central‑nervous‑system‑active substances or medications that may enhance sedation should be avoided while a child is receiving a second‑generation antihistamine. 35

Management of Allergic Rhinitis and Nasal Congestion with Cetirizine

Symptom Relief in Allergic Rhinitis

• Cetirizine 10 mg once daily significantly reduces rhinorrhea, sneezing, itching, and ocular symptoms in both seasonal and perennial allergic rhinitis, achieving efficacy comparable to other second‑generation antihistamines such as fexofenadine, loratadine, and desloratadine. 36

Limited Effect on Nasal Congestion

• Cetirizine provides only modest objective improvement of nasal congestion; when congestion is a dominant symptom, adding an intranasal corticosteroid is recommended rather than switching to another oral antihistamine. 36

Algorithmic Recommendation for Prominent Congestion

• In patients with marked nasal congestion, the preferred strategy is to combine any oral antihistamine (including cetirizine) with an intranasal corticosteroid, because oral antihistamines alone have limited impact on congestion. 36

Antihistamine Efficacy for Nasal Congestion and Sedation Guidance

Nasal Congestion Control

• In patients with seasonal allergic rhinitis, both fexofenadine and loratadine demonstrate limited objective improvement of nasal congestion, indicating that oral antihistamines alone are insufficient for this symptom. 37
• When nasal congestion is the predominant complaint, clinical guidelines recommend adding an intranasal corticosteroid rather than switching between oral antihistamines, because intranasal corticosteroids provide superior comprehensive symptom control. 37

Sedation Profile and Guideline Consensus

• The American Academy of Allergy, Asthma, and Immunology states that fexofenadine, loratadine, and desloratadine are non‑sedating at their approved doses; however, fexofenadine uniquely retains a non‑sedating profile even at doses exceeding the FDA‑approved maximum, making it the preferred option when avoidance of sedation is critical. 37

Guideline for Loratadine Monotherapy and Loratadine‑Pseudoephedrine Combination in Allergic Rhinitis

Indications and Choice of Therapy

• Use loratadine 10 mg once daily as first‑line therapy when rhinorrhea, sneezing, nasal itching, and ocular symptoms predominate and nasal congestion is absent or only mild; oral antihistamines effectively control these symptoms but provide minimal objective relief of obstruction. 38
• Add pseudoephedrine 120 mg twice daily (extended‑release loratadine 5 mg + pseudoephedrine 120 mg) only when nasal congestion is the dominant symptom and the patient has no cardiovascular contraindications; this combination is superior to loratadine alone for relieving nasal stuffiness (p < 0.01) while maintaining control of other allergic symptoms. 38

Patient Populations Requiring Special Consideration

• Choose loratadine alone for patients who must avoid stimulant effects (e.g., insomnia, anxiety, palpitations, hypertension, cardiac arrhythmias, angina, cerebrovascular disease, hyperthyroidism, bladder‑neck obstruction, glaucoma). 38
• Loratadine monotherapy is appropriate for elderly patients and young children because pseudoephedrine carries heightened risk of cardiovascular and central‑nervous‑system adverse effects in these groups. 38
• Loratadine at the recommended 10 mg dose does not cause sedation; the incidence of sedation (~3%) is comparable to placebo and markedly lower than that of first‑generation antihistamines. 38

Contraindications to Pseudoephedrine

• Absolute contraindications: uncontrolled hypertension, severe coronary artery disease, concurrent monoamine‑oxidase‑inhibitor therapy, and hypersensitivity to sympathomimetic amines. 38
• Relative contraindications (require careful risk‑benefit assessment): controlled hypertension, cardiac arrhythmias, angina pectoris, cerebrovascular disease, hyperthyroidism, diabetes mellitus, bladder‑neck obstruction (benign prostatic hypertrophy), and narrow‑angle glaucoma. 38
• Elderly patients are at increased risk for cardiovascular and central‑nervous‑system adverse effects from pseudoephedrine, including confusion, hallucinations, and hemodynamic instability. 38

Clinical Decision Algorithm

• Absent or mild congestion → prescribe loratadine 10 mg once daily alone. 38
• Moderate‑to‑severe congestion without cardiovascular contraindications → prescribe extended‑release loratadine 5 mg + pseudoephedrine 120 mg twice daily. 38
• Severe congestion with cardiovascular contraindications to pseudoephedrine → switch to intranasal corticosteroid monotherapy, which provides superior relief of nasal congestion without cardiovascular risk. 38
• When combination therapy is desired but pseudoephedrine is contraindicated → add an intranasal corticosteroid to loratadine rather than adding pseudoephedrine. 38

Comparative Efficacy

• The loratadine‑pseudoephedrine combination yields a significantly greater reduction in composite symptom scores than either component alone; 58 % of patients achieve a good or excellent therapeutic response versus lower response rates with monotherapy. 38
• Neither loratadine alone nor the loratadine‑pseudoephedrine combination provides substantial relief of nasal congestion compared with intranasal corticosteroids, which remain the most effective medication class for comprehensive allergic rhinitis control. 38
• Intranasal corticosteroids are superior to both loratadine monotherapy and the loratadine‑pseudoephedrine combination for patients with moderate‑to‑severe allergic rhinitis, especially when nasal congestion is prominent. 38

Safety and Risk‑Management Recommendations

• Screen all patients for absolute and relative cardiovascular contraindications before adding pseudoephedrine; serious adverse events such as hypertensive crisis, myocardial infarction, and stroke have been reported with sympathomimetic decongestants. 38
• Do not use the loratadine‑pseudoephedrine combination as first‑line therapy when nasal congestion is not the dominant symptom, to avoid unnecessary stimulant side effects without added benefit. 38
• Reassess the need for pseudoephedrine periodically; discontinue long‑term use when acute congestion resolves and consider transitioning to loratadine alone or to intranasal corticosteroids. 38